VANCOUVER, April 8 /CNW/ - Medifocus Inc. (TSXV; MFS) announced that positive clinical results, that demonstrate significant efficacy when using the Company's proprietary focused heat treatment in combination with Standard of Care (SOC) preoperative (neo-adjuvant) chemotherapy for large breast cancer tumors, were presented during the Market Opening Ceremony of Medifocus at the Toronto Stock Exchange on March 25, 2009 and also at the 19th National Interdisciplinary Breast Center Conference held March 14-18, 2009 in Las Vegas, Nevada., The patient data were obtained from a multi-center, randomized clinical study to demonstrate improvement in tumor shrinkage when focused heat is used in combination with SOC neo-adjuvant chemotherapy. This study was conducted in the USA under an Investigational Device Exemption (IDE) issued by the Food and Drug Administration (FDA).
